We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TERIFLUNOMIDE-REDDY'S, TERIFLUNOMIDE-DRLA, TERIFLUNOMIDE-RZ, TERIFLUNOMIDE-DR.REDDY'S (Dr Reddys Laboratories Australia Pty Ltd)
Product name
TERIFLUNOMIDE-REDDY'S, TERIFLUNOMIDE-DRLA, TERIFLUNOMIDE-RZ, TERIFLUNOMIDE-DR.REDDY'S
Date registered
Evaluation commenced
Decision date
Approval time
150 working days (255)
Active ingredients
teriflunomide
Registration type
New generic medicine
Indication
TERIFLUNOMIDE-REDDY'S, TERIFLUNOMIDE-DRLA, TERIFLUNOMIDE-RZ, TERIFLUNOMIDE-DR.REDDY'S (tablets) are indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.